June 22, 2017 10:12 PM ET


Company Overview of MaxCyte, Inc.

Key Executives for MaxCyte, Inc.

NameBoard RelationshipsTitleAge
Douglas Arthur Doerfler 119 RelationshipsCo-Founder, President, Chief Executive Officer & Executive Director60
Ronald Evan Holtz CPA6 RelationshipsCompany Secretary, CFO & Executive Director58
Debra K. Bowes M.TNo RelationshipsExecutive Vice President of Business & Strategic Development--
Madhusudan Viswanath Peshwa Ph.D.1 RelationshipsChief Scientific Officer & Executive VP of Cellular Therapies48

MaxCyte, Inc. Board Members*

NameBoard RelationshipsPrimary CompanyAge
J. Stark Thompson Ph.D. 6 RelationshipsMaxCyte, Inc.74
Douglas Arthur Doerfler 119 RelationshipsMaxCyte, Inc.60
Ronald Evan Holtz CPA 6 RelationshipsMaxCyte, Inc.58
William W. Brooke J.D. 28 RelationshipsWallace, Jordan, Ratcliff & Brandt59
Arthur Michael Mandell 23 RelationshipsPrestwick Pharmaceuticals, Inc.63
View All Board Members

MaxCyte, Inc. Executive Committees*

Committee NameChairpersonBoard RelationshipsMembers
Audit Committee J.D.William W. Brooke28 Relationships1 Executives
Compensation Committee Ph.D.J. Stark Thompson6 Relationships2 Executives
Nominating Committee Arthur Michael Mandell23 Relationships3 Executives
View Committee Details
*Data is at least as current as the most recent Definitive Proxy.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup


  Industry Range
Total Short Term Compensation$584.0K
Total Value of Options
Compensation as of Fiscal Year
MaxCyte, Inc. CEO Compensation
Industry Average


Biohaven Pharmaceutical Holding Company Ltd. and Biohaven Pharmaceuticals, Inc. Announce Executive Appointments
June 22, 2017 7:00 AM ET
ValiRx plc Announces Executive Changes
June 22, 2017 6:00 AM ET
Affimed N.V. Appoints Wolfgang Fischer as New Managing Director
June 21, 2017 8:31 PM ET
Five Prime Therapeutics, Inc. Announces Executive Changes
June 21, 2017 8:11 PM ET
OvaScience, Inc. Announces Executive Changes
June 21, 2017 8:07 PM ET

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact MaxCyte, Inc., please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.